Scarica l'app Stockscreener
449.74
2.19%
-10.07
Dopo l'orario di chiusura:
447.35
-2.39
-0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Zacks Investment Research
Madrigal Pharmaceuticals stock gets fresh Rezdiffra data - AD HOC NEWS
A liver drug improved disease measures across several genetic risk groups - Stock Titan
Under an automatic trading plan, director Paul Friedman proposes to sell shares in Madrigal Pharmaceuticals (MDGL). - Stock Titan
Madrigal Grants Equity Awards to 27 New Employees - MyChesCo
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - stocktitan.net
Madrigal Pharma CEO William John Sibold disposes of common shares worth $4.16 million - Bitget
Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Canada
Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com UK
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - stocktitan.net
September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews
Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo
Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - manilatimes.net
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 27% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Madrigal Grants Stock Awards to 13 New Employees - MyChesCo
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Report: Analysts See 31% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - stocktitan.net
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - stocktitan.net
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - stocktitan.net
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - Yahoo Finance
Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo
Madrigal Pharmaceuticals Inc (0JXI) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Madrigal Pharmaceuticals Adds Renowned Leader to Board - The Globe and Mail
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan - Kalkine Media
2.44%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):